Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer... Show more
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for the treatment of cancer. Headquartered in Rockville, Maryland, and traded on the Nasdaq under the ticker MGNX, the company is best known for its proprietary antibody engineering platforms and for advancing several investigational medicines into clinical trials. Investors follow the stock because of its oncology pipeline, its partnerships with larger pharmaceutical companies, and its track record of generating FDA-approved products through its research programs.
MacroGenics was incorporated in 2000 and completed its initial public offering in 2013. Its operations are centered on Rockville, Maryland, where it also operates a commercial-scale manufacturing facility. The company's core expertise lies in engineering antibodies — the proteins the immune system uses to recognize and attack foreign or diseased cells — and redirecting them against cancer targets.
The company's business model is built on two complementary pillars. First, it advances its own proprietary product candidates through preclinical and clinical development. Second, it enters collaboration and license agreements with larger partners that provide upfront payments, development and regulatory milestones, and royalties in exchange for rights to specific programs. Notable collaborators have included INCY (Incyte), GILD (Gilead Sciences), and Sanofi.
MacroGenics' technology platforms include its DART (Dual-Affinity Re-Targeting) and TRIDENT bispecific molecules, which bind two different targets at once, as well as antibody-drug conjugates (ADCs) that link an antibody to a cell-killing payload. Its current proprietary pipeline includes lorigerlimab, a bispecific molecule targeting the checkpoint proteins PD-1 and CTLA-4; MGC026, an ADC targeting B7-H3; and MGC028, an ADC targeting ADAM9, among other early-stage programs.
Three products originating from MacroGenics' pipeline have received U.S. Food and Drug Administration (FDA) approval. MARGENZA (margetuximab-cmkb), a treatment for certain patients with HER2-positive metastatic breast cancer, was sold to TerSera Therapeutics. TZIELD (teplizumab-mzwv), approved to delay the onset of Stage 3 type 1 diabetes, was acquired by Provention Bio and is now marketed by Sanofi. ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor, was licensed to Incyte. MacroGenics retains economic interests in these products through milestones and royalties, which contribute to its revenue.
Investors monitor MGNX for several reasons. The company's proprietary antibody platforms give it a differentiated position in immuno-oncology, a field focused on harnessing the immune system against cancer. Its ADC and bispecific programs target validated and emerging cancer antigens, and its partnerships with established pharmaceutical companies provide both external validation and non-dilutive funding.
The company's financial profile is typical of a development-stage biotechnology firm: it generates meaningful revenue from collaborations, milestones, royalties, and contract manufacturing, while incurring substantial research and development expenses. In fiscal 2025, MacroGenics reported approximately $149.5 million in total revenue and a net loss, reflecting the high cost of advancing a clinical pipeline. Management has indicated that its cash position and anticipated partner payments are expected to fund operations into late 2027.
A key long-term driver is the potential for its pipeline candidates to become commercially successful therapies, which could unlock future milestone and royalty income. Its contract manufacturing business also provides a secondary revenue stream and helps utilize its Rockville facility.
Investing in MGNX carries risks common to clinical-stage biotechnology companies. Drug development is lengthy, expensive, and uncertain; clinical trials can fail, and regulatory approval is never guaranteed. MacroGenics has a history of net losses and an accumulated deficit, and it may need to raise additional capital or enter new partnerships to sustain its pipeline.
Clinical setbacks represent a specific risk. The company has previously discontinued or altered development programs based on interim data, and its investigational candidates can face regulatory holds related to safety events. MacroGenics also depends heavily on collaborators for funding and for the commercialization of approved products, which means its revenue can be lumpy and influenced by partners' decisions. Competition in oncology is intense, and the company operates in a sector subject to evolving healthcare regulation and reimbursement pressures.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. For investors researching oncology and biotechnology names such as MGNX, the screener offers a structured way to compare companies and refine a watchlist.
MacroGenics occupies a distinct niche in oncology drug development, combining proprietary bispecific and ADC platforms with a partnership-driven business model. Its track record of producing FDA-approved products — most of which were monetized through collaborators — demonstrates the productivity of its research engine, even as the company continues to operate at a loss while advancing its pipeline. For investors, MGNX represents exposure to the high-risk, high-reward world of clinical-stage biotechnology, where scientific progress and partnership economics largely determine long-term value.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology